Impax Still Needs To Fix Production Plant Issues, FDA Says
A U.S. Food and Drug and Administration inspection has again found problems with Impax Laboratories Inc.'s California manufacturing plant, potentially further delaying Impax's proposed Parkinson's disease treatment Rytary, the drugmaker announced...To view the full article, register now.
Already a subscriber? Click here to view full article